⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 10, 2026Diabetes Obesity and Metabolism

Rethinking Muscle Health Assessment in GLP ‐1–Based Therapies for Obesity: Beyond Lean Mass

Mojca Jensterle Andrej Janež

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate how muscle health is assessed in GLP-1-based treatments for obesity, beyond just focusing on lean mass.
Analysis of current muscle health assessment techniques.
Review of GLP-1 therapy effectiveness in obesity management.
Discussion of additional factors impacting muscle health.
Current assessments may overlook critical aspects of muscle health.
A comprehensive approach is necessary for better treatment outcomes.
Beyond lean mass, factors like muscle function and quality are crucial.

Implication

This assessment reveals the need for a broader understanding of muscle health in obesity therapies, indicating potential improvements.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jensterle et al. (2026) studied this question.

synapsesocial.com/papers/69b3aad702a1e69014ccb852 https://doi.org/10.1111/dom.70649

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Are Women Living With Obesity More Responsive to <scp>GLP</scp> ‐1 Receptor Agonists? A Potential Signal From Trial‐Level and Within‐Trial AnalysesReview · 2026
2Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trialeditorial · 2025 · 2 citations
32923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity MedicationsOriginal Research · 2026
42614-P: Understanding the Lived Experiences of Dosing Practices among People Living with Obesity (PwO) Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Weight Loss (WL): A U.S. Qualitative StudyOriginal Research · 2026
5<scp>TOS</scp> / <scp>OMA</scp> / <scp>OAC</scp> Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to ActionSystematic Review · 2026

More related papers

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology2026
1666-P: Orforglipron and Markers of Insulin Sensitivity and Beta-Cell Function by Prediabetes Status in Adults with Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial2026
2768-LB: Evaluation of a Nutrition Program Using a Diabetes-Specific Formula with Beta-hydroxy-beta-methylbutyrate (HMB) on Metabolic and Muscle Health in Patients with Type 2 Diabetes With or at Risk of Malnutrition2026

More from Diabetes Obesity and Metabolism

How Well Are We Measuring Nausea? A Narrative Review of Patient‐Reported Outcome Gaps in GLP ‐1 Receptor Agonist Obesity TrialsThu,
Sustained Versus Minimal GLP ‐1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without DiabetesThu,